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The docetaxel–carboplatin combination is active and well tolerated in patients with epithelial ovarian cancer. We added
epirubicin to this combination to investigate additional beneﬁts of anthracyclines in epithelial ovarian cancer. Twenty-one
patients, FIGO Ic-IV, performance status 0–1, were treated in four dose cohorts. Docetaxel was ﬁxed at 75 mg m
72,
carboplatin doses were AUC 4–5 and epirubicin doses were 50–60 mg m
72. Drugs were given on day 1, every 3 weeks,
except in cohort 3, where epirubicin was given on day 8. Dexamethasone was given prophylactically. One dose-limiting
toxicity occurred in cohorts 1, 2 and 4, two occurred in cohort 3. Complicated neutropenia occurred in two patients in
cohorts 1 and 2 and one patient in cohorts 3 and 4. Two patients experienced grade III diarrhoea or stomatitis in cohort 1
and two in cohort 3. There were no treatment-related deaths. Grade II sensory neuropathy occurred in one patient. No
cardiac toxicity or signiﬁcant oedema was observed. The overall response rate was 36%, and 62% were CA125 responders.
The predeﬁned maximum tolerated dose was exceeded in cohort 3. The cohort 4 dose level (epirubicin 50 mg m
72,
carboplatin AUC 4, docetaxel 75 mg m
72), warrants further study.
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Cancer of the ovary is the fourth most common cause of cancer
death in women, and is the leading cause of gynaecological cancer
death in the developed world (Boring et al, 1992). Around 90% of
cases are epithelial carcinomas, and approximately 75% will have
spread beyond the ovaries at the time of diagnosis (Young et al,
1993). Because of this advanced presentation, only a minority of
women will have surgically curable localised disease, and conse-
quently systemic chemotherapy has become the mainstay of
treatment. The high response rates observed with chemotherapy
have not readily translated into major long-term survival gains,
and the overall 5-year survival is still less than 30% (Neijt et al,
1991). The need for new therapeutic strategies is therefore clear.
Combination chemotherapy with cisplatin has achieved higher
response rates and improved median survival in randomised trials
(Advanced Ovarian Cancer Trialist Group, 1991), and combination
chemotherapy with cisplatin and an alkylating agent remained
standard treatment for advanced ovarian cancer until recently. In
1996, a randomised trial from the Gynaecologic Oncology Group
(GOG) demonstrated clear superiority of cisplatin combined with
paclitaxel (McGuire et al, 1996), a result conﬁrmed in the
European Intergroup study (Piccart et al, 2000). Paclitaxel–cispla-
tin was rapidly adopted worldwide as the standard of care in this
setting. Interestingly, GOG 132 (Muggia et al, 2000) showed no
survival advantage for paclitaxel–cisplatin over either drug given
as monotherapy. One interpretation of this trial is that patients
who did not receive paclitaxel during the study may have received
it following disease progression, thus essentially having sequential
treatment. Therefore, the sequential administration of these agents
may be as efﬁcacious as concomitant combination, although the
trial was not speciﬁcally designed to examine this hypothesis.
Substitution of carboplatin for cisplatin in combination with
paclitaxel has resulted in a reduced incidence of emesis and neuro-
toxicity, albeit at the expense of greater myelosuppression, and is
supported by data from three randomised studies (Neijt et al,
1997; Ozols et al, 1999; du Bois et al, 1999). Results from these
trials justify the choice of carboplatin–paclitaxel as preferred
ﬁrst-line treatment, with equivalent efﬁcacy and superior tolerabil-
ity compared with cisplatin–paclitaxel.
Docetaxel (Taxotere
1) has demonstrated substantial single-agent
efﬁcacy that is at least comparable to paclitaxel in advanced, plati-
num-refractory ovarian cancer (Kaye et al, 1997) and has also been
combined with cisplatin in a multicentre pilot/feasibility study
(Vasey et al, 1999). The feasibility of a carboplatin–docetaxel
combination as ﬁrst-line chemotherapy for patients with advanced
epithelial ovarian cancer has been explored in a large, multicentre
dose-ﬁnding study (Vasey et al, 2001a). Here, signiﬁcant neurotoxi-
city was unusual, although myelosuppression was common. Despite
this, sepsis was rare and neither prophylactic antibiotics nor growth
factors were routinely necessary. The overall response rate was 66%,
although 75% of patients fulﬁlled CA125 response criteria. Carbo-
platin AUC 5 and docetaxel 75 mg m
72 were considered worthy of
further investigation. Carboplatin AUC 5 and docetaxel
75 mg m
72 have been used in a randomised phase III study
comparing docetaxel–carboplatin with paclitaxel–carboplatin
(Vasey et al, 2001b). Preliminary results suggest that these two
treatment arms have comparable efﬁcacy, with a signiﬁcantly lower
incidence of neurotoxicity in the docetaxel–carboplatin arm vs
paclitaxel–carboplatin, providing additional evidence for the activ-
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also been successfully administered to patients with ovarian, perito-
neal and fallopian tube malignancies (Markman et al, 2001).
There is evidence for additional beneﬁt when incorporating an
anthracycline into combination chemotherapy regimens for
advanced ovarian cancer. Four randomised trials have compared
an anthracycline-containing regimen – cyclophosphamide, adria-
mycin and cisplatin (CAP) – with a non-anthracycline con-
taining regimen – cisplatin and cyclophosphamide (CP) (Conte
et al, 1986; Bertelsen et al, 1987; Omura et al, 1989; GICOG,
1992). All of these trials demonstrated a slight non-signiﬁcant
trend towards a survival advantage for CAP. Furthermore, a
published overview of two large meta-analyses, using individualised
data from over 1700 untreated patients, demonstrated that the
addition of anthracycline signiﬁcantly improved survival (HR
0.85, P=0.03) (A’Hern and Gore, 1995). The most commonly used
anthracycline is doxorubicin; however, epiruibicin is known to
have essentially the same spectrum of activity, with less cardiotoxi-
city, and therefore a more favourable toxicity proﬁle. In addition,
epirubicin 60 mg m
72 has been added to the combination of
paclitaxel 175 mg m
72 and carboplatin AUC 7, with a high
response rate and manageable toxicities (Hill et al, 1997).
In this study, we added epirubicin to the docetaxel plus carbo-
platin combination in order to determine the feasibility and safety
of the combination in patients with advanced ovarian cancer.
MATERIALS AND METHODS
Patients
Eligible women had histologically veriﬁed epithelial ovarian cancer,
were over 18 years old, and had FIGO stages Ic–IV with or with-
out successful cytoreductive surgery at staging laparotomy. Stage Ic
disease was limited to patients with malignant cells in ascitic ﬂuid
or peritoneal washings, pre-operative capsular rupture or surface
tumour. Stage Ic patients with intra-operative ruptured capsule
only were ineligible. Patients were required to have an ECOG
performance status of 42, and adequate bone marrow and hepatic





71, bilirubin5upper limit of normal (ULN), amino-
transferases AST/ALT 51.56LTLN, alkaline phosphatase (ALP)
536ULN. Adequate renal function was required and deﬁned by
serum creatinine 51.256ULN. Written, informed consent, in
compliance with the recommendations of the Declaration of
Helsinki, was obtained in all cases.
Patients were ineligible for study entry if they had received prior
treatment with chemotherapy or radiotherapy, or had any prior
malignancy (except for curatively treated carcinoma in situ of the
uterine cervix or basal cell carcinoma of the skin). Patients with
borderline ovarian tumours or abdominal adenocarcinoma of
unknown origin were excluded, as were those with clinically signif-
icant pleural effusions or ascites unless conﬁrmed cytologically to
be due to ovarian cancer. Patients were also ineligible if there
was a history of medically signiﬁcant atrial or ventricular
dysrrhythmias, congestive heart failure, angina pectoris or docu-
mented myocardial infarction within the 6 months preceding
study entry. A pretreatment electrocardiogram (ECG) showing
evidence of infarction with no other clinical features did not
preclude study entry. Additional contraindications included: active
infection or serious intercurrent illness that was judged by the
investigators likely to impair the patient’s ability to receive protocol
therapy; a history of prior serious allergic reactions; and sympto-
matic peripheral neuropathy4grade II. Pregnant or lactating
women were ineligible, but potentially fertile women using
adequate contraception were allowed treatment. A diagnosis of
insulin-dependent diabetes mellitus or other relative contraindica-
tions to corticosteroid administration were discussed with the
investigators prior to enrolment.
Treatment plan and administration
Epirubicin 50–60 mg m
72, docetaxel 75 mg m
72 and carboplatin
AUC 4–5 were administered consecutively on day 1 of a 21-day
cycle in three of four treatment cohorts. In cohort 3, epirubicin
50 mg m
72 was administered on day 8 (Table 1). The anticipated
total number of cycles was six. Carboplatin dosing was determined
prior to the ﬁrst cycle by the formula (glomerular ﬁltration rate
(GFR) + 25)6desired AUC (Calvert et al, 1989), where the GFR
was measured by
51Cr EDTA (Chantler et al, 1969). This dose
remained ﬁxed throughout subsequent cycles, unless de-escalation
was required as a result of toxicity. Patients who had either a
partial response or stable disease after six cycles were allowed to
receive further chemotherapy with three cycles of single-agent
carboplatin, AUC 5–7, depending on the clinician’s preference.
On the completion of ﬁrst-line chemotherapy, patients ceased all
cytotoxic chemotherapy until documented clinical progression.
The appropriateness of either second-look or interval cytoreductive
surgery was determined on an individual patient basis, as this was
not a protocol requirement. Six patients were entered into each
dose cohort until they had completed two full treatment cycles.
Escalation to the next dose cohort proceeded if fewer than two
of the six patients developed dose-limiting toxicity (DLT) during
Cycles 1 or 2. Dose-limiting toxicity was deﬁned as any of the
following toxicities occurring in the ﬁrst two cycles of treatment:
(a) complicated or prolonged grade IV neutropenia; (b) compli-
cated grade IV thrombocytopenia and/or a need for platelet
transfusion; (c) any grade III non-haematological toxicity excluding
emesis and alopecia. The maximum tolerated dose (MTD) was
deﬁned as the dose level at which two or more of the ﬁrst six
patients followed up for two complete cycles experienced a DLT.
Premedication consisted of oral dexamethasone, 8 mg bid for 3
days, starting the day before chemotherapy. Epirubicin was admi-
nistered over approximately 15 min into the side port of a fast-
ﬂowing drip. Docetaxel was reconstituted in 250 ml of 5% glucose
solution and administered by intravenous infusion over 60 min.
Carboplatin was then administered in 500 ml of 5% glucose solu-
tion over 30–60 min. Prophylactic intravenous antiemetics (8 mg
dexamethasone plus either 3 mg granisetron or 8 mg ondansetron)
were administered to all patients, and were timed to be given
immediately prior to the epirubicin injection. All patients were
routinely prescribed oral domperidone 20 mg tid or qid as
required, for 5–7 days following chemotherapy.
Dose and schedule modiﬁcations
Treatment was administered on day 1 of each planned 21-day cycle





71; values less than this necessitated a
treatment delay until recovery. In cohort 3, epirubicin was admi-
nistered on day 8, irrespective of full blood count. Any delay of
more than 2 weeks for haematological recovery necessitated termi-
nation of protocol therapy. Dose reductions were based upon nadir
blood counts. Any grade IV neutropenia that lasted at least 7 days
and/or was complicated by fever resulted in a reduction of doce-
taxel dose by 15 mg m
72 on all subsequent cycles. Any such
neutropenic events were treated at the time with antibiotics, and
granulocyte colony stimulating factor (G-CSF) was added if consid-
ered appropriate by the investigator. The occurrence of
neutropenic fever also resulted in prophylactic oral antibiotics
(ciproﬂoxacin 250 mg bid days 5–15) being prescribed for each
subsequent treatment cycle. If complicated or prolonged neutro-
penia occurred again, despite dose reductions and prophylactic
antibiotics, subsequent cycles were delivered with subcutaneous
G-CSF 300 mg day
71 from days 5–14 or until the neutrophil
count was 41.0 10
9 l
71 and rising. If this was considered inap-
propriate, the remaining cycles of chemotherapy were
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72 and carboplatin AUC 5. Grade IV thrombocytopenia
requiring platelet transfusion and/or complicated by haemorrhage
resulted in a reduction of the carboplatin dose by 10% in all subse-
quent cycles.
Abnormalities of hepatic function, as evidenced by AST/ALT
and/or ALP elevations to4grade I during treatment, resulted in
the patient’s withdrawal from protocol therapy and continued
treatment with carboplatin as a single agent.
Treatment delays were planned for patients who developed severe
skin toxicity (4grade II) for a maximum of 2 weeks until recovery
to 5grade I, when they could be re-treated with a 10–15 mg m
72
reduction of docetaxel. Mucositis 4grade II necessitated a treat-
ment delay of maximum 2 weeks until resolution of lesions, and
a subsequent docetaxel dose reduction as above. No dose reductions
were planned on the basis of docetaxel-induced ﬂuid retention. The
development of grade III/IV neurotoxicity – motor, sensory or
otological – necessitated termination of protocol therapy.
Mild hypersensitivity reactions were treated by slowing down the
docetaxel infusion. Severe hypersensitivity reactions were termi-
nated with appropriate drug therapy (adrenaline, antihistamines
or corticosteroids, depending upon the severity of the reaction).
Re-challenge after recovery from a hypersensitivity reaction was
allowed if clinically indicated, and was generally done within 3 h.
Later re-challenges (within 3–24 h) were required to be further
premedicated with high-dose dexamethasone and chlorphenira-
mine. Further hypersensitivity reactions necessitated withdrawal
from study.
Patient evaluation and clinical assessments
Patients underwent full physical examination, including vaginal/
rectal examination. Baseline investigations prior to study entry
included: full blood count and differential white cell count,
biochemical proﬁle (including urea, creatinine, sodium, potassium,
calcium, magnesium, AST, ALT, ALP, bilirubin, total protein, albu-
men,
51Cr EDTA measurement of GFR, chest X-ray, glucose),
CA125 and 12-lead ECG. The size and extent of residual disease
were documented by computed tomography (CT) scan of abdo-
men and pelvis. Patients’ weight and ECOG performance status
were noted at baseline.
During chemotherapy, patients were seen weekly for full blood
count, serum chemistry and documentation of treatment-related
toxicity using the National Cancer Institute of Canada Expanded
Common Toxicity Criteria (NCIC-CTC, version 2.0). Prior to each
treatment cycle, patients were weighed and had a full physical
examination plus CA125 estimations. Response to chemotherapy
was assessed after three and six (and, if appropriate, nine) courses
of chemotherapy by the same imaging technique used at baseline.
Clinical and radiological tumour response were graded according
to standard criteria (Miller et al, 1981); CA125 responses were
graded according to the schema from Rustin and co-workers
(Rustin et al, 1996).
Following completion of protocol chemotherapy, patients were
followed-up 2-monthly for the ﬁrst 2 years, 4-monthly to 5 years
and annually thereafter. Pelvic examination was carried out at each
follow-up visit, along with CA125 measurement. CT scans were
carried out if progressive disease was suspected clinically or
CA125 levels began to increase.
Statistical methods
Analysis of variance (ANOVA) techniques were used to compare
cycle 1 nadir neutrophil and platelet counts between cohorts (after
suitable transformations to make the data approximately normal).
Cumulative haematological toxicity was examined using repeated
measures ANOVA. Proportions were compared using Pearson’s
chi-square test (unadjusted). All survival times were dated from
when the patient was registered on the study. Progression-free
survival was the time from registration to progression or death,
from any cause. Survival curves were determined using Kaplan–
Meier estimates.
RESULTS
Twenty-one patients treated at the Beatson Oncology Centre, Glas-
gow, were enrolled in this study. In total, 120 cycles of docetaxel–
carboplatin–epirubicin chemotherapy were administered to these
patients over four dose cohorts (Table 1). Pretreatment patient
characteristics are shown in Table 2. All patients had epithelial
ovarian adenocarcinoma: serous/papillary adenocarcinoma 11
(52%); endometrioid 3 (14%); mucinous 1 (5%); other 1 (5%).
The majority of patients (12 patients; 57%) had poorly differen-
tiated tumours. The median age was 57 years (range 34–68
years). Sixteen patients (73%) were FIGO stage III or IV at presen-
tation, and all patients had a performance status of 0–1. The
majority of patients (12 patients; 57%) had been optimally
debulked prior to treatment.
Toxicity
A total of 19 patients (90%) received the planned six cycles of treat-
ment, and there were no withdrawals from the study because of
toxicity. Haematological toxicity was seen in all treatment cohorts
and is presented in Table 3. Grade IV neutropenia was observed
in 18 patients (86%), with nine patients (43%) experiencing
prolonged (45 days) neutropenia and a further ﬁve patients
(24%) experiencing grade IV neutropenia with fever. In total, 11
patients had complicated or prolonged neutropenia. However, only
one patient had grade IV neutropenia with pyrexia lasting more
than 2 days, and there were no sepsis-related deaths. Four patients
(19%) required a dose delay secondary to neutropenia, one in
cohort 1 and three in cohort 3, and 10 patients (48%) required dose
reductions. Two patients, both in cohort 2, experienced grade IV
thrombocytopenia, but there were neither episodes of haemorrhage
nor any requirement for prophylactic platelet transfusion. Signiﬁ-
cant anaemia was not observed: while almost all patients (20
patients, 95%) experienced anaemia at grade II or III, no patient
had grade IV anaemia. Only one cycle of chemotherapy (Cycle 5,
cohort 1) was delayed due to the need for blood transfusion.
Signiﬁcant non-haematological toxicity was unusual, and treat-
ment was generally well tolerated by patients. The most common









Table 1 Treatment cohorts
Epirubicin Carboplatin Docetaxel No. patients No. No. completing
Cohort (mg m
2) (AUC) (mg m
2) registered cycles six cycles
1 50 5 75 6 36 6 (100%)
2 60 5 75 6 30 4 (67%)*
3 50 (Day 8) 5 75 6 36 6 (100%)
4 50 4 75 3 18 3 (100%)
*One patient had disease progression after two cycles, another after four cycles.
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patients (43%) experienced grade II lethargy. Table 4 lists all
signiﬁcant non-haematological toxicities. There were no reports
of grade IV nausea or emesis. One patient reported grade III
vomiting and three reported grade III nausea. Grade III diarrhoea
was experienced by two patients (10%) and two patients experi-
enced grade III mucositis.
Severe neurotoxicity was not encountered. Two patients (10%)
experienced grade II sensory neuropathy, which had fully resolved
by 7 months. No motor neuropathy was identiﬁed. Two patients
had grade II peripheral oedema, while one patient had grade III
oedema requiring treatment with diuretics. One patient experi-
enced grade III polyarthropathy that had resolved at most recent









Table 2 Pre-treatment characteristics
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Overall
(n=6) (n=6) (n=6) (n=3) (n=2)
% n % n % n % n % n
Performance status
0 83 5 67 4 33 2 100 3 67 14
1 17 1 33 2 67 4 0 0 33 7
Residual disease*
42 cm 100 6 33 2 40 2 67 2 60 12
42 cm 0 0 67 4 60 3 33 1 40 8
Stage
Ic 17 1 0 0 17 1 0 0 19 2
II 17 1 17 1 0 0 33 1 8 3
III 50 3 50 3 67 4 33 1 69 11
IV 17 1 33 2 17 1 33 1 4 5
Degree of differentiation
Well 0 0 0 0 0 0 0 0 0 0
Moderate 33 2 50 3 33 2 0 0 33 7
Poor 67 4 33 2 67 4 67 2 57 12
Unknown 0 0 17 1 0 0 33 1 10 2
Histology
Serous 33 2 17 1 50 3 0 0 29 6
Mucinous 0 0 17 1 0 0 0 0 5 1
Endometrioid 17 1 17 1 17 1 0 0 14 3
Papillary 17 1 33 2 17 1 33 1 24 5
Adenocarcinoma 33 2 17 1 0 0 67 2 24 5
Other 0 0 0 0 17 1{ 00 5 1
Age
Median 58 60 55 42 57
IQ range 51–60 53–68 50–57 34–67 50–61
Range 44–61 40–68 43–67 34–67 34–68
*Details on residual disease not available for one patient in cohort 3. {Papillary serous cystadenocarcinoma.
Table 3 Haematological toxicity (worst grade over cycles received)
Cohort 1 Cohort 2 Cohort 3 Cohort 4
(n=6) (n=6) (n=6) (n=3)
Grade % n % n % n % n
Neutropenia 2 0 0 0 0 0 0 0 0
3 17 1 0 0 33 2 0 0
4 83 5 100 6 67 4 100 3
Complicated neutropenia — 50 3 50 3 50 3 66 2
Leucopenia 2 33 2 0 0 0 0 33 1
3 17 1 0 0 83 5 0 0
4 50 3 100 6 17 1 67 2
Thrombocytopenia 2 33 2 33 2 33 2 0 0
3 0 0 17 1 17 1 0 0
4 00 3 32 00 00
Anaemia 2 83 5 83 5 67 4 67 2
31 7 1 1 7 1 3 3 20 0
40 0 0 0 0 0 0 0
Dose delays from — 17 1 0 0 50 3 0 0
neutropenia
Dose reductions from — 33 2 50 3 50 3 67 2
neutropenia
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tion, which took the form of generalised urticaria. After stopping
the infusion, the patient was re-challenged with no further
problems.
In summary, the maximum tolerated dose was exceeded in
cohort 3. Overall, there was one DLT in cohort 1, one in cohort
2, two in cohort 3 and one in cohort 4. In addition, a further
two patients experienced complicated neutropenia in cohort 1,
two in cohort 2, one in cohort 3 and one in cohort 4 (Table 5).
Two patients experienced grade 3 diarrhoea or stomatitis in cohort
1 and two in cohort 3. There were no treatment-related deaths.
Response and survival
Eleven patients (52%) had radiologically evaluable disease at outset:
four patients (19%) had a complete response, three patients (14%)
had stable disease and four (19%) had progression of their disease.
The overall radiological response rate is therefore 36%. Sixteen
patients were evaluable for CA125 response, 10 of whom satisﬁed
strict Ruskin criteria to qualify as responders (62%). The median
follow-up for living patients is 20 months (range 17–22 months).
The median progression-free survival time is 12 months (95%
CI=6–18 months) and the 1-year survival rate is 62% (SE=11%).
DISCUSSION
We report here the ﬁrst experience of carboplatin, epirubicin and
docetaxel in combination as ﬁrst-line treatment for advanced
epithelial ovarian cancer. The theoretical basis for this combination
is clear, since these three classes of drugs are non-cross-resistant
and show signiﬁcant activity in ovarian cancer. In addition, there
are in vitro data suggesting that synergy exists between taxanes
and anthracyclines (Bruckner et al, 1994).
As anticipated, the myelosuppressive capacity of this regimen
was high but nevertheless manageable. Overall, 86% of patients
experienced grade IV neutropenia, somewhat less than that
reported for the combination of paclitaxel, anthracycline and plati-
num treatment (i.e. 100%) in a similar patient population
(Gregory et al, 2000). However, 11 patients (51%) experienced
complicated or prolonged neutropenia. The incidence of thrombo-
cytopenia in our patients was less than in the study cited (18 vs
50%). The fact that neutropenia was not accompanied by sepsis
in the majority (81%) of cases is probably attributable to the low
incidence of grade III/IV mucositis or diarrhoea. Nevertheless,
grade III and IV toxicities occurred in cohorts 1–3 and dose
reductions and delays were seen as a consequence. Administration
of epirubicin on day 8 in cohort 3 was done in an attempt to
reduce the incidence of grade IV neutropenia, albeit at the expense
of an additional day’s visit to the clinic. Dose limiting toxicities
were however still observed. The dose level used in cohort 4 –
namely epirubicin 50 mg m
72, carboplatin AUC 4 and docetaxel
75 mg m
72 – is in theory worthy of further study. However, a
carboplatin dose of AUC 4 (albeit calculated via measured GFR)
may be considered suboptimal therapy, even in combination treat-
ment. For this reason, cohort 4 was stopped after the accrual of
three patients. Routine use of G-CSF support has been shown to
substantially reduce myelosuppression in high-dose treatment of
breast cancer patients receiving 250 mg m
72 paclitaxel,
90 mg m
72 doxorubicin and 3 mg m
72 cyclophosphamide (Hudis
et al, 1995). One option would therefore be to include G-CSF in
the schedule. An alternative would be to substitute pegylated
doxorubicin (Muggia et al, 1997) for epirubicin, since this might
be expected to result in a reduced rate of myelosuppression, albeit
at the expense of other non-haematological toxicities such as
hand–foot syndrome.
Neurotoxicity was not a signiﬁcant problem with this regimen,
which conﬁrms data for docetaxel–carboplatin alone. Only two
patients (10%) reported mild sensory neuropathy, which fully
resolved over several months, in concordance with the reported
low incidence of neurotoxicity for single-agent docetaxel. The
striking lack of neurotoxicity with this regimen is in contrast to
the signiﬁcant neurotoxicity of paclitaxel and paclitaxel-containing
combinations, and provides a cogent argument for making doce-
taxel the taxane of choice in this setting. Survival comparisons
of docetaxel and paclitaxel plus carboplatin are awaited – in
particular, mature data from the SCOTROC trial (Scottish Rando-
mised Trial in Ovarian Cancer). Preliminary results from this
study (Vasey, 2001b), in which the combination of docetaxel–
carboplatin was compared with paclitaxel–carboplatin, suggest
that the former combination is signiﬁcantly less neurotoxic than
paclitaxel–carboplatin (sensory neuropathy occurred in 11% and
30% of patients, respectively; P50.001). Docetaxel-related periph-
eral oedema was mostly preventable with steroid pre-medication,
and only one patient experienced a moderate hypersensitivity reac-
tion to the drug.
Cardiac function was not measured objectively in this study,
since it was felt that the incidence of cardiotoxicity in anthracy-
cline-naı ¨ve patients, particularly with the use of epirubicin, was
likely to be very low. Consequently, careful clinical assessment
failed to reveal any development of cardiac dysfunction during
the study.
Objective response rates in this trial were less than might have
been expected, and less than in other published series of anthra-
cycline–platinum–taxane treated patients (Gregory et al, 2000).
For example, in the SCOTROC study, both objective and
CA125 response rates were similar in patients treated with either
docetaxel–carboplatin or paclitaxel–carboplatin (Vasey, 2001b).
The lower response rates observed in our study are likely to be
a consequence of both the small patient sample and possibly a
combination of the frequent dose delays and reductions required
in response to toxicity, as 52% of patients required a dose reduc-
tion during treatment. It is worth noting that only 50% of
patients in the present study had radiologically evaluable disease
and therefore comparison of response rates with other studies is
inappropriate. The CA125 response rate (62%) is more in line
with expected response rates. However, this trial was initiated as
a toxicity/feasibility study and comparisons of efﬁcacy between
phase I and II studies are not informative.
In spite of great progress in the treatment of ovarian cancer,
several questions remain unanswered. One concerns the best taxoid









Table 4 Non-haematological toxicities
Cohort 1 Cohort 2 Cohort 3 Cohort 4
(n=6) (n=6) (n=6) (n=3)
Grade % n % n % n % n
Alopecia 3 67 4 67 4 83 5 33 1
Nausea 3 17 1 17 1 17 1 0 0
Vomiting 3 0 0 17 1 0 0 0 0
Diarrhoea 3 17 1 0 0 17 1 0 0
Oedema 3 0 0 0 0 0 0 33 1
Stomatitis 3 17 1 0 0 17 1 0 0
Tiredness/ 2 33 2 50 3 50 3 33 1
lethargy
Sensory 2 0 0 0 0 17 1 33 1
neuropathy
Table 5 Summary of dose-limiting and other grade III/IV toxicities
Cohort 1 Cohort 2 Cohort 3 Cohort 4
DLT 1/6 1/6 2/6 1/3
Other grade III/IV toxicity 4/6 2/6 3/6 2/3
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patients with advanced ovarian cancer, in particular the reduced
incidence of neurotoxicity in docetaxel-containing combinations,
compared with those containing paclitaxel. The optimum adminis-
tration schedule is also under active debate, in particular the
scheduling of cytotoxics. This might take the form of examining
alternating doublets, as in GOG 182. In this ﬁve arm, prospective,
randomised trial, which aims to accrue over 5000 patients, four
cycles of gemcitabine–carboplatin followed by four cycles of pacli-
taxel–carboplatin will be compared with four cycles of liposomal
doxorubicin–carboplatin followed by four cycles of paclitaxel–
carboplatin, four cycles of topotecan–carboplatin followed by four
cycles of paclitaxel–carboplatin, eight cycles of gemcitabine–pacli-
tacel–carboplatin and eight cycles of paclitaxel–carboplatin.
Substitution of pegylated doxorubicin for epirubicin, as in the
above study, could be expected to produce less myelosuppression
and therefore fewer dose reductions and delays. An alternative
approach is to utilise sequential scheduling, whereby the new agent
is delivered either alone or in combination after initial treatment
with carboplatin. Sequential chemotherapy has become ﬁrmly
established in the treatment of breast cancer (Bonadonna et al,
1995). The feasibility of this approach is also being examined in
the SCOTROC-2 study programme, which is currently recruiting
patients in the UK and Europe. This randomised Phase III trial
is comparing four cycles of single-agent carboplatin followed by
four cycles of docetaxel alone or in combination with CPT-11 or
gemcitabine. Results are expected in the ﬁrst quarter of 2002.
In conclusion, the combination of carboplatin–epirubicin–
docetaxel shows activity in patients with ovarian cancer, but toxi-
city-induced dose reductions and delays may limit its utility. There
were no patient withdrawals as a result of toxicity, and the striking
lack of neurotoxicity in this study is in line with docetaxel–carbo-
platin administration. The recently reported AGO–GINECO trial,
examining the use of paclitaxel-carboplatin with or without epiru-
bicin, has to date failed to show any signiﬁcant advantage for the
triple combination (all given on day 1), although follow-up is short
(du Bois et al, 2001). Therefore, further studies should examine the
role of scheduling in the activity and tolerability of these agents.
REFERENCES
Advanced Ovarian Cancer Trialist Group (1991) Chemotherapy in advanced
ovarian cancer: an overview of randomized clinical trials. Br Med J 303:
884–893
A’Hern RP, Gore ME (1995) Impact of doxorubicin on survival in advanced
ovarian cancer. J Clin Oncol 13: 726–732
Bertelsen K, Jakobsen A, Andersen JE et al (1987) A randomized study of
cyclophosphamide and cis-platinum with or without doxorubicin in
advanced ovarian carcinoma. Gynecol Oncol 28: 161–169
Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating
doxorubicin and CMF regimens in breast cancer with more than three
positive nodes. Ten-year results. JAMA 273: 542–547
Boring CC, Squires TS, Tong T (1992) Cancer statistics. CA 42: 19–38
Bruckner HW, Cagnoni PJ, Lee JM et al (1994) A sequence of adriamycin and
Taxol
1 infusions for refractory ovarian cancer. Proc Am Soc Clin Oncol 13:
276
Calvert AH, Newall DR, Gumbrell LA et al (1989) Carboplatin dosage:
prospective evaluation of a simple formula based on renal function. J Clin
Oncol 7: 1748–1756
Chantler C, Garnett ES, Parsons V et al (1969) Glomerular ﬁltration rate
measurement in man by the single injection method using
51CrEDTA. J
Clin Sci 37: 169–190
Conte PF, Bruzzone M, Chiara S et al (1986) A randomized trial comparing
cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclo-
phosphamide in advanced ovarian cancer. J Clin Oncol 4: 965–971
du Bois A, Lueck HJ, Meier W et al (1999) Cisplatin/paclitaxel vs carboplatin/
paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekolo-
gische Onkologie (AGO) study group trial. Proc Am Soc Clin Oncol 18:
1374 [Abstr]
du Bois A, Weber B, Pﬁsterer J, Goupil A, Wagner U, Barats J, Olbricht S,
Mousseau M, Nitz U, Meden H for the AGO-GINECO Intergroup
(2001) Epirubicin/Paclitaxel/Carboplatin (TEC) vs. Paclitaxel/Carboplatin
(TC) in ﬁrst line treatment of ovarian cancer FIGo stages IIb-IV. Interim
results of an AGO-GINECO Intergroup phase III trial. Proc Am Soc Clin
Oncol 20: 202a [Abstr]
GICOG, (Gruppo Interregionale Cooperativo Oncologico Ginecologia), Italy
(1992) Long-term results of a randomized trial comparing cisplatin with
cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and
adriamycin in advanced ovarian cancer. Gynecol Oncol 45: 115–117
Gregory RK, Hill ME, Moore J et al (2000) Combining platinum, paclitaxel
and anthracycline in patients with advanced gynaecological malignancy.
Eur J Cancer 36: 503–507
Hill M, Macfarlane V, Moore J et al (1997) Taxane/platinum/anthracycline
combination therapy in advanced epithelial ovarian cancer. Semin Oncol
24(Suppl 2): 34–37
Hudis CA, Seidman AD, Baselga J et al (1995) Sequential adjuvant therapy
with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer
involving four or more axillary nodes. Semin Oncol 22: 18–23
Kaye SB, Piccart MJ, Aapro M et al (1997) Phase II trials of docetaxel (Taxo-
tere) in advanced ovarian cancer — an updated overview. Eur J Cancer 33:
2167–2170
Markman M, Kennedy A, Webster K et al (2001) Combination chemotherapy
with carboplatin and docetaxel in the treatment of cancers of the ovary and
fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19:
1901–1905
McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and
cisplatin compared with paclitaxel and cisplatin in patients with stage III
and stage IV ovarian cancer. N Engl J Med 334: 1–6
Miller AB, Hoogstraten S, Staquet M, Winkler M (1981) Reporting results of
cancer treatment. Cancer 74: 207–214
Muggia FM, Hainsworth JD, Jeffers S et al (1997) Phase II study of liposomal
doxorubicin in refractory ovarian cancer: antitumor activity and toxicity
modiﬁcation by liposomal encapsulation. J Clin Oncol 15: 987–993
Muggia FM, Braly PS, Brady MF et al (2000) Phase III randomized study of
cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with
suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group
study. J Clin Oncol 18: 106–115
Neijt JP, Ten Bokkel HuininkWW, Van der Berg MEL et al (1991) Long term
survival in ovarian cancer. Eur J Cancer 17: 1367–1372
Neijt JP, Hansen M, Hansen SW et al (1997) Randomised phase III study in
previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV,
comparing paclitaxel–cisplatin and paclitaxel–carboplatin. Proc Am Soc
Clin Oncol 16: 1259 [Abstr]
Omura GA, Bundy BN, Berek JS et al (1989) Randomized trial of cyclopho-
sphamide plus cisplatin with or without doxorubicin in ovarian
carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7: 457–465
Ozols RF, Bundy BN, Fowler J et al (1999) Randomized phase III study of
cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in opti-
mal stage III epithelial ovarian cancer (OC): a Gynaecologic Oncology
Group Trial (GOG 158). Proc Am Soc Clin Oncol 18: 356a [Abstr 1373]
Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of
cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with
advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst
92: 699–708
Rustin GJ, Nelstrop AE, McClean P et al (1996) Deﬁning response of ovarian
carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol
14: 1545–1551
Vasey PA, Paul J, Junor EJ et al (1999) Docetaxel–cisplatin in combination as
ﬁrst-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol
17: 2069–2080
Vasey PA, Atkinson R, Coleman R et al (2001a) Docetaxel–carboplatin as
ﬁrst line chemotherapy for epithelial ovarian cancer. Br J Cancer 84:
170–178
Vasey PA on behalf of the Scottish Gynecologic Cancer Trials Group (2001b)
Preliminary results of the SCOTROC trial: a phase III comparison of pacli-
taxel–carboplatin (PC) and docetaxel–carboplatin (DC) as ﬁrst-line
chemotherapy for stage Ic–IV epithelial ovarian cancer (EOC). Proc Am
Soc Clin Oncol 20: [Abstr 804]
Young RC, Perez CA, Hoskins WJ (1993) Cancer of the ovary. In Cancer:
Principles and Practice of Oncology, 4th edn, DeVita VT, Hellman S, Rosen-









Carboplatin–epirubicin–docetaxel in ovarian cancer
VJ O’Neill et al
1390
British Journal of Cancer (2002) 86(9), 1385–1390 ã 2002 Cancer Research UK